GynecologyNews.net

Gynecology Xagena

Metabolic markers to predict the risk of preeclampsia: 14 metabolites in early pregnancy identified


Researchers used a combination of sophisticated emerging technologies and data analysis to detect 14 simple metabolites with high accuracy to predict in early pregnancy which women are at risk of developing preeclampsia in later pregnancy. Currently there is no predictive test for the condition and no cure other than delivery of the newborn.

The study is published in Hypertension.

Preeclampsia is a life-threatening condition characterized by high blood pressure and high levels of protein in the urine. The condition is thought to begin in early pregnancy with defective development of the placenta but most often does not show symptoms until the second half of pregnancy. Preeclampsia can endanger the lives of both mother and child and is a leading cause of maternal death.

This condition suggests women do not become sick and present with preeclampsia until late in pregnancy, but the condition originates in early pregnancy. To develop effective treatment and prevention strategies, the treatment should start in early pregnancy.

Researchers studied women in SCOPE ( Screening for Pregnancy Endpoints ), an international trial of approximately 7,000 women with first-time pregnancies which aims to predict and prevent the major diseases of late pregnancy.

In the case control study, researchers first discovered and evaluated the detection rate of the test in women at 15 weeks’ gestation with low risk of preeclampsia in Auckland, New Zealand. The 60 fit, healthy, first-time pregnant women ( average age 30 ) later developed preeclampsia. They were matched with a control group of 60 women.

The study’s second phase validated the initial findings in an entirely different group of women in Adelaide, Australia. These women were younger, with an average age of 22-23 and were ethnically more diverse compared to the predominantly Caucasian group in New Zealand. Thirty-nine women subsequently developed preeclampsia later after the early test. There were 40 matched controls.

The researchers are trying to simplify the technology to develop a single blood test for the bedside that will be cheap and readily accessible to hospitals everywhere.

In the United States and in the developed world, preeclampsia affects 4-5% of pregnant women, but may reach 10% in the developing world. The World Health Organization estimates that from 100,000 to 200,000 women die each year as a direct cause of preeclampsia. ( Xagena )

Source: American Heart Association 2010

XagenaMedicine_2010



Indietro